Hollis-Eden Pharmaceuticals, Inc.
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone HE3235 at AACR Molecular Targets and Cancer Therapeutics Conference
Published in Medical Imaging Law Weekly, December 1st, 2009
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)." Apoptone (HE3235), a novel steroid that is an analog of a dihydrotestosterone metabolic pathway member, stimulates cell death (apoptosis) in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Law Weekly
More Articles from Medical Imaging Law Weekly
- Abscess
Research data from P. Tabrizian and colleagues update understanding of abscess - Acute Pancreatitis
New acute pancreatitis study results reported from Y.K. Kim et al - Adenoma
Findings from S. Paggi and co-authors provide new insights into adenoma - Alzheimer Disease
Research from AstraZeneca provides new data on Alzheimer disease - Alzheimer Disease
Researchers at Columbia University, Taub Institute for Research on Alzheimer's Disease and the Aging Brain release new data on Alzheimer disease - American College of Radiology
USPSTF Mammography Recommendations Will Result in Countless Unnecessary Breast Cancer Deaths Each Year - More from this issue of Medical Imaging Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
